33results about How to "Inhibition of apoptosis" patented technology

The extracorporeal culture and mature method of immature oocyte from ovary tissue block includes selecting marrow mesenchyme stem cell MSC of female mouse as the feeder cell, compounding MSC culture liquid and agar and covering the culture rack, adding HCG in 3 IU / ml, and adhering the ovary tissue block on the rack to culture. In the co-culture system, estradiol, progestin and luteotopin contents are increased obviously, and after culturing, there is mature oocyte discharged. The method is significant in surviving rear endangered species of animals, breeding fine variety of animal, cell biological research of embryo stem cell, etc.

The present invention is feeder cell for extracorporeal culture of immature oocyte and features that marrow mesenchyme stem cell MSC of female mouse is used as the feeder cell. The feeder cell is easy to obtain, can secrete several kinds of cell factors and growth factors, promote over 90 % of the immature oocyte to become mature and promote the growth, ovulation and maturing of the ovarian follicles in the ovary tissue block under extracorporeal culture. The present invention is significant in surviving rear endangered species of animals, breeding fine variety of animal, cell biological research of embryo stem cell, etc.

The invention relates to genomics, molecular biology, cell biology, gene engineering and clinical medicine, in particular to application of a human ING4 and IL-24 double-gene coexpression vector as a radiotherapy sensitizing agent. Before the radiotherapy, the human ING4 and IL-24 double-gene coexpression vector is led in tumor cells so that the human ING4 and IL-24 genes are expressed in the tumor cells, and then the radiotherapy is carried out. The Ad-ING4-polyA<delta 296-298>+CMV-IL-24 can retard lots of tumor cells in the proliferative stage in the G2 / M stage and is beneficial to enhancing the irradiation sensitivity. The MTT and the FCM detection results further show that the Ad-ING4-IL-24 combined radiotherapy has the effect of obviously inhibiting the growth of the SPC-A1 lung adenocarcinoma cells, MDA-MB-231 breast carcinoma cells and the transplanted tumor thereof and inducing the cell apoptosis, exceeds the Ad-ING4-IL-24 single genome and the radiotherapy single genome, and presents obvious radiotherapy sensitization synergistic effect. Therefore, the human ING4 and IL-24 double-gene coexpression vector can be used for enhancing the sensitivity of the tumor cells to the radiotherapy.

The invention discloses emodin as an inhibitor of activated molecules p-Akt and p-mTOR of a PI3K / Akt / mTOR signal transduction pathway and application thereof, wherein the emodin is a purely natural anthraquinone monomer compound extracted from rhubarb as a Chinese traditional medicine and has multiple biologic activities such as anti-microbes, anti-inflammation, antioxidation, immune regulation, liver protection and the like. The invention finds that after acute leukemia multidrug-resistance cells HL-60 / ADR, acute promyelocytic leukemia retinoic acid drug-resistant cells MR2 as well as corresponding sensitive cells NB4 and acute leukemia primary cells are acted by the rhubarb, key signal activated molecules of the PI3K / Akt / mTOR signal transduction pathway, particularly p-Akt and p-mTOR, are inhabited with specificity; in vivo researches verify that after the emodin is dosed, all the key activated molecules p-Akt, p-p65 and p-mTOR of the PI3K / Akt / mTOR signal pathway in acute leukemia nude mouse transplanted tumor tissue protein are expressed and downwards regulated, which indicates that the emodin can be used as a novel targeting inhibitor for PI3K / Akt / mTOR signal transduction activated molecules, particularly p-Akt and p-mTOR, and is applied to treating malignant tumors of a blood system.

The invention relates to a method for preparing a sappan wood extract, in particular to a method for preparing an irrigating solution with an anti-tumor function. The method solves the problems of extracting sappan woods with specific effects in the prior art. The method comprises the following steps: weighing a certain amount of crushed sappan wood, adding purified water which is 3 to 5 times ofthe crushed sappan wood into the crushed sappan wood, soaking the crushed sappan wood for 12 to 24 hours at the room temperature, boiling the mixture for 30 minutes and separating an extract; adding water into the crushed sappan wood again, boiling the mixture for 30 minutes, extracting the mixture, and separating the extract; adding the purified water into the crushed sappan wood again, boiling the mixture for 30 minutes, extracting the mixture, and separating the extract; and combining the three extracts, performing vacuum concentration on the combined extract until the amount is 12 to 16 percent of the total amount of the added water, freezing and icing the concentrated solution at a temperature of 20 DEG C below zero, taking the frozen and iced concentrated solution out to unfreeze theconcentrated solution naturally at the room temperature, filtering the unfrozen concentrated solution to remove deposits, heating and boiling the concentrated solution obtained in the previous step again, freezing and icing the concentrated solution at a temperature of 20 DEG C below zero, taking the frozen and iced concentrated solution out to unfreeze the concentrated solution naturally at theroom temperature, and filtering the unfrozen concentrated solution to remove the deposits. The obtained product has significant anti-tumor effect.

The invention discloses application of rhizoma polygonati beta-galactan HJW0S300-2 in cosmetics with an antiaging or sun-protecting effect. The structural formula of the rhizoma polygonati beta-galactan is shown in the formula which is shown in the description. The molecular weight is ranged from 8 KDa to 15 KDa, and the average molecular weight Mw is 10 KDa. The invention further relates to application of rhizoma polygonati beta-galactan in inhibiting fibroblast apoptosis and cosmetics containing the rhizoma polygonati beta-galactan.

An embodiment of the invention provides a serum-free epithelial cell culture fluid, and relates to the field of biomedicine. The serum-free epithelial cell culture fluid comprises a basic culture fluid, necessary added factors, growth factors, anchoring factors, hormones, regulatory factors for cell proliferation and differentiation and an apoptosis inhibitor. By adding a P53 inhibitor, a naturally-extracted antioxygen resveratrol and flavin adenine dinucleotide (FAD) to inhibit apoptosis coordinately, apoptosis during cell culturing can be inhibited, and by adding the regulatory factors for cell proliferation and differentiation, presenility of cells is avoided, so that the serum-free epithelial cell culture fluid is applicable to large-scale multiplication culture of the cells.

The invention discloses a method for extracting anthocyanins from berry fruits. The method comprises the following steps: (1) beating the berry fruits into pulp, adding an ethanol aqueous solution andextracting; purifying the extract liquid by macroporous resin, evaporating to recover a solvent by rotary evaporation, concentrating the extract liquid, and freeze-drying in vacuum to obtain crude anthocyanin extracts; and (2) separating an anthocyanin crude extract solution by simulated moving bed chromatography, to obtain the anthocyanin extracts. The anthocyanin extracts in the berry fruits are separated and purified by macroporous resin and the simulated moving bed, the anthocyanin extracts with fewer impurities are separated out, and then the anthocyanin extracts for resisting senility are prepared. The method realizes industrialized production of the anthocyanin extracts so as to improve the production efficiency of the anthocyanins. The anthocyanins can be used alone or combined infood or medicines, and are made into any dosage form of health care products or medicines, and anthocyanins of aronia melanocarpa elliot, mulberry, grapes and the like have the function of delaying senility.

The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis-specific eIF-5A or eIF5-A1, nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of apoptosis-specific eIF-5A. The invention also relates to suppressing or inhibiting expression of pro-inflammatory cytokines or inhibiting activation of NFkB by inhibiting expression of apoptosis-specific eIF-5A.

The invention discloses an application of 4,4'-dimethoxy chalcone in delaying of in-vivo and in-vitro aging of an oocyte. The invention discloses an application of the 4,4'-dimethoxy chalcone in preparation of a reagent for delaying an in-vitro aging process of the oocyte. The invention discloses an application of the 4,4'-dimethoxy chalcone in preparation of a medicine for improving reproductive aging. Results of the invention show that the DMC can be used for effectively improving the quality of in-vitro-aged MII-stage oocytes, and in-vitro fertilization experiments verify that the fertilization rate and blastocyst development rate of the aged MII-stage oocytes can be effectively improved by adding the DMC into a culture medium. By adding the DMC into a culture solution for in-vitro-aged MII oocytes of a mouse, the in-vitro aging process of the MII-stage oocytes can be effectively delayed, the oocyte quality is improved, and the ovulation rate can be effectively increased when an elderly mouse orally takes the DMC.

The invention relates to the field of biology and medical drugs, and discloses the function of miR-148 on proliferation and apoptosis of pancreatic beta cells, which provides a new target spot for diabetes treatment as well as preparation or screening of drugs for curing 2-type diabetes. According to the invention, miR-148 can be applied to the preparation or screening of drugs for controlling pancreatic beta cells, and preparation or screening of drugs for controlling apoptosis of pancreatic beta cells, or preparation or screening of drugs for curing 2-type diabetes.

The invention belongs to the field of drug preparation and application, and particularly relates to application of a ribosome S6 kinase inhibitor SL0101 in the preparation of a drug for treating cardiovascular diseases. The invention aims at providing the drug for treating the cardiovascular diseases, wherein the drug contains a substance for performing treatment by taking an orphan nuclear receptor Nr4a3 as a drug target. Preferably, the effective component of the substance comprises the ribosome S6 kinase inhibitor SL0101. The application of the orphan nuclear receptor Nr4a3 as a target in the preparation of a drug for screening the cardiovascular diseases provides a very wide prospect and important significance for drug application of the ribosome S6 kinase inhibitor SL0101.

The invention belongs to the technical field of biological medicines, and discloses application of intervening BOK in preparation of a medicine for treating novel coronavirus pneumonia. In order to find a new immunotherapy scheme for comprehensive treatment of novel coronavirus pneumonia, the research on the lung tissue of novel coronavirus pneumonia patients finds that the expression quantity of BOK in the lung tissue cell of the novel coronavirus pneumonia patients is increased, BOK gene knockout can inhibit the apoptosis of human lung cells and vascular endothelial cells induced by a novel coronavirus membrane protein, and BOK knockdown by injecting lentivirus into the trachea of a mouse to express shRNA (short hairpin Ribonucleic Acid) aiming at BOK can inhibit the apoptosis of the lung tissue induced by the novel coronavirus membrane protein, which indicates that BOK is expected to be applied to the comprehensive treatment of the novel coronavirus pneumonia and is prepared into the form of a medicine for treating the novel coronavirus pneumonia, which can relieve lung injury and alveolar cavity fluid infiltration of the novel coronavirus pneumonia patients, and is suitable for protecting lung tissues and organs in the novel coronavirus pneumonia process.

The invention discloses a medicine for treating cutaneous squamous cell carcinoma and a preparation method of the medicine. The medicine comprises the following materials in parts by weight: 4-6 parts of roots of Chinese pulsatilla, 2-4 parts of curcuma zedoary and 1-3 parts of ginger. The preparation method of the medicine comprises the following steps: adding 70% ethanol into medicinal materials for extracting for three times, wherein the addition amount of ethanol is 12 times that of the medicinal materials and the extraction is carried out for 2 hours each time, combining filter liquor and concentrating to be fluid extract with the ratio of 1:1.3, placing into a thermotank with the temperature of 65-75 DEG C to dry into hard brittle pieces, and thus obtaining the medicine by storing at a low temperature and in a dry place. The medicine for treating cutaneous squamous cell carcinoma can obviously inhibit the proliferation of cutaneous squamous cell carcinoma A431 cells, meanwhile has effects on inducing the apoptosis of A431 cells, and also can prevent the cells from staying at a G0 / G1 period so as to prevent the DNA synthesis of an S period and inhibit the proliferation of tumor cells.

The invention provides an application of peroxy-ergosterol in preparation of a drug for preventing or treating influenza virus infection, and provides a method for separating peroxy-ergosterol from isatis roots simultaneously. The application of a small molecular compound peroxy-ergosterol in preparation of the drug for preventing or treating the influenza virus infection is provided by the invention, so that the effective drug for preventing and treating clinical influenza currently is provided. The inventor finds that peroxy-ergosterol can effectively inhibit influenza virus induced host cells from overexpressing a pattern recognition receptor RIG-I for pathogen recognition, so that effects of abnormal immune inflammation and mediated apoptosis transduced and mediated with pattern recognition receptor downstream signals are inhibited.

The present invention provides a recombinant polypeptide with protective function on pancreatic islet beta-cells, wherein the encoding sequence of the recombinant polypeptide is clarified through PCR, based on N-sequence of LVGPIGAVGP of shark hepatic active peptide, with shark hepatic cDNA as the template, while the secreted expression vector of the recombinant polypeptide is constructed, the acquired recombinant polypeptide is capable of suppressing the STZ-induced apoptosis of pancreatic islet cells NIT-1 in vitro.

The extracorporeal culture and mature method of immature oocyte from ovary tissue block includes selecting marrow mesenchyme stem cell MSC of female mouse as the feeder cell, compounding MSC culture liquid and agar and covering the culture rack, adding HCG in 3 IU / ml, and adhering the ovary tissue block on the rack to culture. In the co-culture system, estradiol, progestin and luteotopin contentsare increased obviously, and after culturing, there is mature oocyte discharged. The method is significant in surviving rear endangered species of animals, breeding fine variety of animal, cell biological research of embryo stem cell, etc.

The invention relates to the technical field of medicine synthesis, and provides a cholic acid derivative as well as a preparation method and application thereof. The cholic acid derivative provided by the invention has a remarkable effect of inhibiting hepatocyte apoptosis, can effectively inhibit hepatocyte damage induced by glycochenodeoxycholic acid, and the inhibition rate of part of the derivative is superior to that of a positive control tauroursodeoxycholic acid; the cholic acid derivative provided by the invention provides a reference for research and development of liver protection drugs, and has a wide application prospect in preparation of the liver protection drugs.

The invention discloses an application of a potentilla fruticosa extract in preparation of a medicine for preventing, treating or inhibiting eye cell apoptosis. Eye cell apoptosis is induced by mycophenolic acid morpholine ethyl ester, and the ocular histopathology of the eye cell apoptosis is ocular cell fixation shrinkage and chromatin edge set. In a zebra fish eye cell apoptosis model, the potentilla fruticosa extract can obviously inhibit eye cell apoptosis and has a remarkable eye protection effect. The invention provides a novel method for resisting apoptosis of eye cells, and corresponding thinking and data are provided for clinical application.

The present invention is feeder cell for extracorporeal culture of immature oocyte and features that marrow mesenchyme stem cell MSC of female mouse is used as the feeder cell. The feeder cell is easy to obtain, can secrete several kinds of cell factors and growth factors, promote over 90 % of the immature oocyte to become mature and promote the growth, ovulation and maturing of the ovarian follicles in the ovary tissue block under extracorporeal culture. The present invention is significant in surviving rear endangered species of animals, breeding fine variety of animal, cell biological research of embryo stem cell, etc.

The invention relates to the field of biology and medical drugs, and discloses the function of miR-148 on proliferation and apoptosis of pancreatic beta cells, which provides a new target spot for diabetes treatment as well as preparation or screening of drugs for curing 2-type diabetes. According to the invention, miR-148 can be applied to the preparation or screening of drugs for controlling pancreatic beta cells, and preparation or screening of drugs for controlling apoptosis of pancreatic beta cells, or preparation or screening of drugs for curing 2-type diabetes.

The invention discloses application of levo-camphor in preparation of a drug for preventing and treating ischemic stroke, relating to the field of medicines. The application of levo-camphor in preparation of the drug for preventing and treating ischemic stroke is characterized in that the drug is a composition composed of levo-camphor and pharmaceutically acceptable carriers; the use dosage of the levo-camphor is about 0.3-0.9 mg / kg for a human body; and the drug composition can be prepared into injections, dropping pills, tablets, hard capsules, soft capsules or oral liquid.

The invention discloses application of sambucus williamsii in alcoholic bone remodeling, osteonecrosis and osteoporosis. The root bark of sambucus williamsii contains a large amount of morroniside, can promote the proliferation of cells for promoting the maximum content of monomers in effective parts for fracture healing, has no toxicity, can well inhibit cell apoptosis, and can change the decrease or increase of the expression of the protein, so the treatment effects on alcoholic remodeling, osteonecrosis and osteoporosis are good; sambucus williamsii leaves are bitter and cool, can activate blood, remove blood stasis and relieve pain and are used for traumatic fractures, rheumatic arthralgia and arthralgia and myalgia; sambucus williamsii flowers are used for sweating and inducing diuresis; and the sambucus williamsii is used for dispelling wind, inducing diuresis, activating blood and relieving pain and is used for rheumatic arthralgia, lumbago, edema, rubella, urticaria, postpartum anemic fainting, traumatic swelling and pain, fracture and traumatic hemorrhage. Therefore, the sambucus williamsii active ingredients have good effects on alcoholic remodeling, osteonecrosis and osteoporosis, and has no toxicity.

The method of obtaining immature oocyte from ovary tissue through separating or extracting for extracorporeal culture includes selecting marrow mesenchyme stem cell MSC of female mouse as the feeder cell or culturing the immature oocyte in the MSC culture liquid. After culturing, the co-culture system has obviously increased estradiol, progestin and luteotopin contents, and over 90 % of the immature oocyte become mature. The method is significant in surviving rear endangered species of animals, breeding fine variety of animal, cell biological research of embryo stem cell, etc.

The invention relates to a method for preparing a sappan wood extract, in particular to a method for preparing an irrigating solution with an anti-tumor function. The method solves the problems of extracting sappan woods with specific effects in the prior art. The method comprises the following steps: weighing a certain amount of crushed sappan wood, adding purified water which is 3 to 5 times ofthe crushed sappan wood into the crushed sappan wood, soaking the crushed sappan wood for 12 to 24 hours at the room temperature, boiling the mixture for 30 minutes and separating an extract; adding water into the crushed sappan wood again, boiling the mixture for 30 minutes, extracting the mixture, and separating the extract; adding the purified water into the crushed sappan wood again, boiling the mixture for 30 minutes, extracting the mixture, and separating the extract; and combining the three extracts, performing vacuum concentration on the combined extract until the amount is 12 to 16 percent of the total amount of the added water, freezing and icing the concentrated solution at a temperature of 20 DEG C below zero, taking the frozen and iced concentrated solution out to unfreeze the concentrated solution naturally at the room temperature, filtering the unfrozen concentrated solution to remove deposits, heating and boiling the concentrated solution obtained in the previous step again, freezing and icing the concentrated solution at a temperature of 20 DEG C below zero, taking the frozen and iced concentrated solution out to unfreeze the concentrated solution naturally at theroom temperature, and filtering the unfrozen concentrated solution to remove the deposits. The obtained product has significant anti-tumor effect.

The invention relates to an application of miR-223 or an inhibitor thereof in a product or a drug of kawasaki disease diagnosis and therapy. Serum miR-223 is obviously increased in an infant with kawasaki disease, so that kawasaki disease diagnosis can be assisted. The invention also relates to an application of the MiR-223 and the inhibitor thereof in up-regulating and down-regulating an insulin-like growth factor-1 receptor (IGF-1R) gene so as to accelerate apoptosis of endothelial cells or inhibiting proliferation of the endothelial cells. The microRNA or the inhibitor thereof provided by the invention can serve as a drug component and may be applied to treating the kawasaki disease in the future.